Prospective Randomised Multicenter Study for Therapy Optimization (First Line) of Advanced Progredient, Low Malignant Non-Hodgkin Lymphomas and Mantle Cell Lymphomas.

Trial Profile

Prospective Randomised Multicenter Study for Therapy Optimization (First Line) of Advanced Progredient, Low Malignant Non-Hodgkin Lymphomas and Mantle Cell Lymphomas.

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Bendamustine (Primary) ; Rituximab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine
  • Indications Follicular lymphoma; Lymphoid leukaemia; MALT lymphoma; Mantle-cell lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms StiL NHL1 study
  • Most Recent Events

    • 06 Jun 2017 Nine-years results of patients with indolent lymphomas (n=447) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 21 Feb 2013 Results published in Lancet.
    • 11 Dec 2012 Results of a subgroup analysis have been presented at the Annual Meeting of the American Society of Hematology (ASH) in December 2012 according to a Mundipharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top